Welcome — VIDAZA is the first drug approved by the US Food and Drug Administration (FDA) for the treatment of all 5 FAB subtypes of myelodysplastic syndromes (MDS).
VIDAZA is indicated for treatment of patients with the following French-American-British
(FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia
with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia
or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory
anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic
Please see full Prescribing Information.
VIDAZA® is a registered trademark of and Celgene Patient Support™ is a trademark of Celgene Corporation.
©2010 Celgene Corporation. All rights reserved.
This site is intended for US audiences only.
Prescribing Information |
Contact Us |